Research

Theranostics Clinical Research Program

Theranostics Clinical Research Program

Theranostics Clinical Research Program, Jeremie Calais, MD, PhD

Theranostics is the combination of tumor-specific targeted radionuclide imaging and therapy.

The Ahmanson Translational Theranostics Division (ATTD) is a Division of the Department of Molecular and Medical Pharmacology (DMMP). The Division includes the Nuclear Medicine clinic, the Biomedical Cyclotron, as well as basic and translational research groups and labs. Fueled by the adoption of Positron Emission Tomography (PET/CT) and stimulated by major new Theranostics and therapeutic opportunities in prostate cancer and neuroendocrine tumors, the Division and Nuclear Medicine clinic has expanded significantly. Novel therapeutic approaches, together with advanced molecular imaging assays, have given rise to the field of Theranostics, the combination of tumor-specific targeted radionuclide imaging and therapy. Very specific clinical and research expertise is now required to master all aspects of Nuclear Medicine, Molecular Imaging and Theranostics.

Dr. Jeremie Calais MD PhD has established a clinical Theranostics research program that combines academic investigator-initiated and industry sponsored studies using targeted radionuclide imaging and therapy. The clinical research program focuses on translatable radiolabeled theranostic pairs that can be used and applied for diagnosis and therapy of cancer. We collaborate closely with clinical faculty across many departments at UCLA (Urology, Radiation Oncology, Radiology, Medical Oncology, Oncologic Surgery) but also with multiple national and international collaborators. Our group has submitted jointly with UCSF an academic NDA for 68Ga-PSMA-11, a major achievement for academia.

Meet Our Team

Research Physicians

Johanna Enke, MD

Johanna Enke, MD

Nuclear Medicine

Position: Research MD
Role: Clinical Research

Eri Kimura, MD, PhD

Eri Kimura, MD, PhD

Position: Research MD
Role: Clinical Research

Koichiro Kimura, MD, PhD

Koichiro Kimura, MD, PhD

Nuclear Medicine

Position: Research MD
Role: Clinical Research

Johnathan Massachi, MD

Johnathan Massachi, MD

Position: Research MD
Role: Clinical Research

image placeholder

Moradi Tuchayi, MD

Position: Research MD
Role: Clinical Research

Research Managers

Stephanie Lira, BS

Stephanie Lira, BS

Position: Clinical Trials Program Manager
Role: Clinical Research and Administration Oversight

Office Phone: x60596

Rejah Marie Nabong, MBA

Rejah Marie Nabong, MBA

Position: Clinical Research Manager
Role: Clinical Research Operations, Study Coordination, Therapy, & Diagnostic

Office Phone: x67372

Clinical Research Coordinators

Kiara Adame, BS

Kiara Adame, BS

Position: Clinical Research Coordinator
Role: Study Coordination, Therapy, and Diagnostic

Office Phone: x67372

Maria Contreras, BS

Maria Contreras, BS

Position: Clinical Research Coordinator
Role: Study Coordination, Therapy, and Diagnostic

Office Phone: x67372

Gabriella Diaz, BA

Gabriella Diaz, BA

Position: Clinical Research Coordinator
Role: Study Coordination, Therapy, and Diagnostic

Office Phone: x67372

Yuzin Arias Gonzalez, MPH

Yuzin Arias Gonzalez, MPH

Position: Clinical Research Coordinator
Role: Study Coordination, Therapy, and Diagnostic

Office Phone: x67372

Lela Theus, BA

Lela Theus, BA

Position: Clinical Research Coordinator
Role: Study Coordination, Therapy, and Diagnostic

Office Phone: x67372

Staff Research Associate

Andrew Nguyen, BS

Andrew Nguyen, BS

Position: Staff Research Associate
Role: Data Analysis and Data Entry

Office Phone: x62466

Publications

Recent Publications (2021 – July 2025)

  1. Mercier A, De Leiris N, Calais J, Ludwig VB, Farolfi A, Gafita A, Djaileb L. PSMA/FDG discordance: 24-hour [177Lu]-PSMA-617 SPECT versus 60-minute [68Ga]-PSMA-11 PET. Eur J Nucl Med Mol Imaging. Published online July 24, 2025. doi:10.1007/s00259-025-07482-x
  2. Juarez Casillas JE, Nikitas J, Rettig MB, Reiter RE, Lee A, Steinberg ML, Valle L, Kalbasi TR, Calais J, Czernin J, Eala MA, Tsai S, Kane N, Solanki AA, Sexton R, Duriset S, Berenji GR, Aronson WJ, Garraway IP, Chang MG, Kwon R, Lee SP, Nickols NG, Kishan AU. Pooled Analysis of the SOLAR and SATURN Clinical Trials Comparing Progression of Synchronous Versus Metachronous Prostate-specific Membrane Antigen-defined Oligometastatic Prostate Cancer Following Systemic and Tumor-directed Therapy. Eur Urol Oncol. Published online June 19, 2025. doi:10.1016/j.euo.2025.05.027
  3. Kuo PH, Calais J, Crosby M. PSMA PET Imaging in the Management of Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Radioligand Therapy. Target Oncol. Published online May 26, 2025. doi:10.1007/s11523-025-01151-7
  4. Czernin J, Anderson CJ, Badawi RD, Barthel H, Bengel FM, Beyer T, Buvat I, Calais J, Dorbala S, Drzezga AE, Herrmann K, Hope TA, Jadvar H, Mankoff DA, Schelbert HR, Weber WA. Funding Reductions Threaten the Future of Medical Innovation. J Nucl Med. 2025;66(6):829. Published 2025 Jun 2. doi:10.2967/jnumed.125.270157
  5. Gafita A, Djaileb L, Calais J, Eiber M, Fendler WP. RECIP 1.0: A Roadmap for Clinical Implementation. J Nucl Med. 2025;66(5):673-675. Published 2025 May 1. doi:10.2967/jnumed.124.268730
  6. Karpinski MJ, Rahbar K, Bagemann M, Nikoukar LR, Schafers M, Hoberück S, Miederer M, Holscher T, Rasul S, Miszczyk M, Lanfranchi F, Bauckneht M, Pfob CH, Kind F, Goffin K, Husing A, Kesch C, Herrmann K, Stuschke M, Gafita A, Husing J, Calais J, Hofman MS, Hope TA, Miksch J, Soeterik TFW, Di Giorgio A, Farolfi A, Bjartell A, Tragardh E, Unterrainer LM, Holzgreve A, Sheikh GT, Rauscher I, Eiber M, Hadaschik BA, Fendler WP. Updated Prostate Cancer Risk Groups by Prostate-specific Membrane Antigen Positron Emission Tomography Prostate Cancer Molecular Imaging Standardized Evaluation (PPP2): Results from an International Multicentre Registry Study. Eur Urol. Published online May 2, 2025. doi:10.1016/j.eururo.2025.04.017
  7. Unterrainer LM, Farolfi A, Grogan T, Hotta M, Djaileb L, Gafita A, Sonni I, Rettig MB, Rosar F, Ezziddin S, Denis CS, de Kouchkovsky I, Aggarwal R, Emmett L, Hope TA, Czernin J, Calais J. Early changes of PSMA PET expression after initiation of androgen receptor signaling inhibitors in CRPC: an international multicenter retrospective study. Eur J Nucl Med Mol Imaging. Published online March 26, 2025. doi:10.1007/s00259-025-07178-2
  8. Hotta M, Nguyen K, Thin P, Armstron WR, Sonni I, Farolfi A, Steinberg M, Czernin J, Nickols NG, Kishan AU, Calais J. Kinetics of PSMA PET signal after radiotherapy in prostate cancer lesions: A single-center retrospective study. Radiother Oncol. 2025;207:110869. doi:10.1016/j.radonc.2025.110869
  9. Murthy V, Ludwig V, Gafita A, Hope TA, Calais J. The Role of PSMA PET Parameters as Biomarkers for Response to PSMA-Targeted Radiopharmaceutical Therapy. J Nucl Med. 2025;66(6):833-838. Published 2025 Jun 2. doi:10.2967/jnumed.124.268818
  10. Ells Z, Ludwig V, Weiner AB, Kimura K, Farolfi A, Chamie K, Shirk J, Donin NM, Reiter R, Czernin J, Calais J (co-last author), Dahlbom M. A free method for patient-specific 3D-VR anatomical modeling for presurgical planning using DICOM images and open-source software. Methods. 2025;236:10-16. doi:10.1016/j.ymeth.2025.02.006
  11. Unterrainer LM, Hope TA, Fendler WP, Grogan T, Ndlovu H, Armstrong W, Barbato F, Benz MR, Rettig MB, Kishan AU, Sathekge M, Herrmann K, Czernin J, Calais J. Low- and High-Volume Disease in Metastatic Hormone-Sensitive Prostate Cancer: From CHAARTED to PSMA PET-An International Multicenter Retrospective Study. J Nucl Med. 2025 Jan 3;66(1):54-60. doi: 10.2967/jnumed.124.268441. PMID: 39753363
  12. Holzgreve A, Armstrong WR, Clark KJ, Benz MR, Smith CP, Djaileb L, Gafita A, Thin P, Nickols NG, Kishan AU, Rettig MB, Reiter RE, Czernin J, Calais J. PSMA-PET/CT Findings in Patients With High-Risk Biochemically Recurrent Prostate Cancer With No Metastatic Disease by Conventional Imaging. JAMA Netw Open. 2025 Jan 2;8(1):e2452971. doi: 10.1001/jamanetworkopen.2024.52971. PMID: 39752157
    MedPageToday: PSMA-PET/CT Detects Metastatic Prostate Cancer Missed by Other Imaging
    AZO Optics: PSMA-PET Challenges Traditional Staging of High-Risk Prostate Cancer
    Renal + Neurology News: PSMA-PET Detects Hidden Metastasis in Recurrent Prostate Cancer
    Inside Precision Medicine: Prostate Cancer Spread Missed By Conventional Imaging
    Urology Times: Conventional imaging may understage prostate cancer, new data suggest
    AuntMinnie: PSMA-PET/CT bests conventional imaging for prostate cancer diagnosis
    The University Network (TUN): Breakthrough PSMA-PET Imaging Reveals Hidden Metastases in Prostate Cancer
    The ASCO Post: Advanced Imaging May Uncover Hidden Metastases in High-Risk Prostate Cancer Cases
    Diagnostic Imaging: Study Emphasizes PSMA PET Staging of High-Risk, Hormone Sensitive Prostate Cancer
    OncoDaily: UCLA: Advanced imaging uncovered hidden metastases in high-risk prostate cancer cases
    UCLA Newsroom: Advanced imaging uncovers hidden metastases in high-risk prostate cancer cases
    Science Daily: Advanced imaging uncovers hidden metastases in high-risk prostate cancer cases
  13. Unterrainer LM, Hope TA, Fendler WP, Grogan T, Ndlovu H, Armstrong W, Barbato F, Benz MR, Rettig MB, Kishan AU, Sathekge M, Herrmann K, Czernin J, Calais J.Low- and High-Volume Disease in Metastatic Hormone-Sensitive Prostate Cancer: From CHAARTED to PSMA PET-An International Multicenter Retrospective Study. J Nucl Med. 2025 Jan 3;66(1):54-60. doi: 10.2967/jnumed.124.268441. PMID: 39753363
    Urology Times: Addition of PSMA PET led to notable stage migration in mHSPC, study shows
  14. Weiner AB, Ells Z, Meyer C, Dahlbom M, Sennung D, Varughese D, Ludwig VB, Carlucci G, Grant R, Czernin J, Calais J(co-last author), Reiter RE. Clinical Responses to Prostate-specific Membrane Antigen Radioguided Salvage Lymphadenectomy for Prostate Cancer Recurrence: Results from a Prospective Exploratory Trial. Eur Urol Open Sci. 2024 Oct 15;70:36-42. doi: 10.1016/j.euros.2024.09.004. eCollection 2024 Dec. PMID: 39483519
  15. Sonni I, Weiner AB, Doddipalli S, Deol M, Ban D, Kim HO, Grogan T, Ahuja P, Barroso N, Zong Y, Soin P, Sisk A, Czernin J, Hsu W, Calais J, Reiter RE, Raman SS. Clinical, Pathologic, and Imaging Variables Associated with Prostate Cancer Detection by PSMA PET/CT and Multiparametric MRI. J Nucl Med. 2024;65(12):1923-1931. Published 2024 Dec 3. doi:10.2967/jnumed.124.268443
    UroToday: Clinical, Pathologic, and Imaging Variables Associated with Prostate Cancer Detection by PSMA PET/CT and Multiparametric MRI
  16. Huang RR, Zuo C, Mona CE, Holzgreve A, Morrissey C, Nelson PS, Brady L, True L, Sisk A, Czernin J, Calais J, Ye H. FAP and PSMA Expression by Immunohistochemistry and PET Imaging in Castration-Resistant Prostate Cancer: A Translational Pilot Study. J Nucl Med. 2024 Oct 30:jnumed.124.268037. doi: 10.2967/jnumed.124.268037. PMID: 39477498
    UroToday: FAP and PSMA Expression by Immunohistochemistry and PET Imaging in Castration-Resistant Prostate Cancer: A Translational Pilot Study
  17. Nikitas J, Gafita A, Benz MR, Djaïleb L, Farolfi A, Hotta M, Sonni I, Alano R, Rettig M, Shen J, Armstrong W, Grogan T, Liu S, Czernin J, Calais J. Phase 2 trial of PSMA PET CT versus planar bone scan and CT in prostate cancer patients progressing while on androgen deprivation therapy.
    Sci Rep. 2024 Oct 18;14(1):24411. doi: 10.1038/s41598-024-75589-6. PMID: 39420060
    Urology Times: Jeremie Calais, MD, highlights study of PSMA-PET vs bone scan in metastatic prostate cancer
  18. Hotta M, Kim GHJ, Rerkpichaisuth V, Teng PY, Armstrong WR, Carlucci G, Dahlbom M, Abtin F, Lari SM, Fishbein GA, Czernin J, Volkmann ER, Weigt SS, Calais J. Correlation of FAPI PET Uptake with Immunohistochemistry in Explanted Lungs from Patients with Advanced Interstitial Lung Disease. J Nucl Med. 2024 Nov 1;65(11):1789-1794. doi: 10.2967/jnumed.124.268351. PMID: 39362770
  19. Murthy V, Voter AF, Nguyen K, Allen-Auerbach M, Chen L, Caputo S, Ledet E, Akerele A, Moradi Tuchayi A, Lawhn-Heath C, Wang T, Carducci MA, Pomper MG, Paller CJ, Czernin J, Solnes LB, Hope TA, Sartor O, Calais J (co-last author), Gafita A. Efficacy and Toxicity of [177Lu]Lu-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer: Results from the U.S. Expanded-Access Program and Comparisons with Phase 3 VISION Data. J Nucl Med. 2024 Nov 1;65(11):1740-1744. doi: 10.2967/jnumed.124.267816. PMID: 39327018
    UroToday: Efficacy and Toxicity of [177Lu]Lu-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer: Results from the U.S. Expanded-Access Program and Comparisons with Phase 3 VISION Data
  20. Weiner AB, Agrawal R, Wang NK, Sonni I, Li EV, Arbet J, Zhang JJH, Proudfoot JA, Hong BH, Davicioni E, Kane N, Valle LF, Kishan AU, Pra AD, Ghadjar P, Sweeney CJ, Nickols NG, Karnes RJ, Shen J, Rettig MB, Czernin J, Ross AE, Lee Kiang Chua M, Schaeffer EM, Calais J, Boutros PC, Reiter RE. Molecular Hallmarks of Prostate-specific Membrane Antigen in Treatment-naïve Prostate Cancer. Eur Urol. 2024 Sep 17:S0302-2838(24)02597-1. doi: 10.1016/j.eururo.2024.09.005. PMID: 39294048
    Urology Times: PSMA levels linked to tumor biology, treatment sensitivity in treatment-naïve prostate cancer
  21. Thin P, Hotta M, Gafita A, Grogan T, Czernin J, Calais J (co-last author), Sonni I. Clinical Factors That Influence Repeat 68Ga-PSMA-11 PET/CT Scan Positivity in Patients with Recurrent Prostate Cancer Under Observation After a Negative 68Ga-PSMA-11 PET/CT Scan: A Single-Center Retrospective Study. J Nucl Med. 2024 Aug 21:jnumed.124.267591. doi: 10.2967/jnumed.124.267591 PMID: 39168522
    UroToday: Clinical Factors That Influence Repeat 68Ga-PSMA-11 PET/CT Scan Positivity in Patients with Recurrent Prostate Cancer Under Observation After a Negative 68Ga-PSMA-11 PET/CT Scan: A Single-Center Retrospective Study
  22. Nikitas J, Castellanos Rieger A, Farolfi A, Seyedroudbari A, Kishan AU, Nickols NG, Steinberg ML, Valle LF, Rettig M, Czernin J, Calais J. Prostate-Specific Membrane Antigen PET/CT-Guided, Metastasis-Directed Radiotherapy for Oligometastatic Castration-Resistant Prostate Cancer. J Nucl Med. 2024 Aug 1:jnumed.124.267922. doi: 10.2967/jnumed.124.267922. PMID: 39089811
    UroToday: Prostate-Specific Membrane Antigen PET/CT-Guided, Metastasis-Directed Radiotherapy for Oligometastatic Castration-Resistant Prostate Cancer
    Diagnostic Imaging: Can Targeted PSMA PET/CT-Guided Radiotherapy Have an Impact for Oligometastatic Prostate Cancer?
  23. Emmett L, Papa N, Hope TA, Fendler W, Calais J, Burger I, Eiber M, Barbato F, Moon D, Counter W, John N, Xue A, Franklin A, Thompson J, Rasiah K, Frydenberg M, Yaxley J, Buteau J, Agrawal S, Ho B, Nguyen A, Liu V, Lee J, Woo H, Hsiao E, Sutherland T, Perry E, Stricker P, Hofman MS, Kasivisvanathan V, Roberts M, Murphy D. Beyond Prostate Imaging Reporting and Data System: Combining Magnetic Resonance Imaging Prostate Imaging Reporting and Data System and Prostate-Specific Membrane Antigen-Positron Emission Tomography/Computed Tomography PRIMARY Score in a Composite (P) Score for More Accurate Diagnosis of Clinically Significant Prostate Cancer. J Urol. 2024 Aug;212(2):299-309. doi: 10.1097/JU.0000000000004010. Epub 2024 May 17. PMID: 38758680
  24. Nikitas J, Subramanian K, Gozal NB, Ricaurte-Fajardo A, Li E, Proudfoot JA, Davicioni E, Marciscano AE, Osborne JR, Barbieri CE, Armstrong WR, Smith CP, Valle LF, Steinberg ML, Boutros PC, Nickols NG, Rettig MB, Reiter R, Weiner AB, Calais J, Czernin J, Ross AE, Kim EH, Nagar H, Kishan AU.Transcriptomic Profiling of Primary Prostate Cancers and Nonlocalized Disease on Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography: A Multicenter Retrospective Study. JCO Precis Oncol. 2024 Jul;8:e2400161. doi: 10.1200/PO.24.00161. PMID: 39013135
  25. Gafita A, Djaileb L, Rauscher I, Fendler WP, Hadaschik B, Rowe SP, Herrmann K, Solnes LB, Calais J, Rettig MB, Weber M, Farolfi A, Benz MR, Eiber M. RECIP 1.0 Predicts Progression-Free Survival After [177Lu]Lu-PSMA Radiopharmaceutical Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer. J Nucl Med. 2024 Apr 18:jnumed.123.267234. doi: 10.2967/jnumed.123.267234. PMID: 38637143 J Nucl Med. 2024 Apr 25:jnumed.123.267004. doi: 10.2967/jnumed.123.267004. PMID: 38664019
  26. Nikitas J, Lam E, Booker KA, Fendler WP, Eiber M, Hadaschik B, Herrmann K, Hirmas N, Lanzafame H, Stuschke M, Czernin J, Steinberg ML, Nickols NG, Kishan AU, Calais J. Randomized Trial of Prostate-Specific Membrane Antigen PET/CT Before Definitive Radiotherapy for Unfavorable Intermediate- and High-Risk Prostate Cancer (PSMA-dRT Trial).
  27. Nikitas J, Rettig M, Shen J, Reiter R, Lee A, Steinberg ML, Valle LF, Sachdeva A, Romero T, Calais J, Czernin J, Nickols NG, Kishan AU. Systemic and Tumor-directed Therapy for Oligorecurrent Metastatic Prostate Cancer (SATURN): Primary Endpoint Results from a Phase 2 Clinical Trial. Eur Urol. 2024;85(6):517-520. doi:10.1016/j.eururo.2024.01.021
  28. Maliha PG, Hotta M, Farolfi A, Grogan T, Alano R, Limon A, Lam E, Carlucci G, Bahri S, Salavati A, Benz M, Silverman D, Gupta P, Quon A, Allen-Auerbach M, Czernin J, Calais J. FAPI PET uptake patterns after invasive medical interventions: a single center retrospective analysis. Eur J Nucl Med Mol Imaging. 2024;51(11):3373-3385. doi:10.1007/s00259-024-06733-7
  29. Weber M, Fendler WP, Ravi Kumar AS, Calais J, Czernin J, Ilhan H, Saad F, Kretschmer A, Hekimsoy T, Brookman-May SD, Mundle SD, Small EJ, Smith MR, Perez PM, Hope TA, Herrmann K, Hofman MS, Eiber M, Hadaschik BA. Prostate-specific Membrane Antigen Positron Emission Tomography-detected Disease Extent and Overall Survival of Patients with High-risk Nonmetastatic Castration-resistant Prostate Cancer: An International Multicenter Retrospective Study. Eur Urol. 2024 Mar 14:S0302-2838(24)00054-X. doi: 10.1016/j.eururo.2024.01.019. PMID: 38490855
  30. Armstrong WR, Kishan AU, Booker KM, Grogan TR, Elashoff D, Lam EC, Clark KJ, Steinberg ML, Fendler WP, Hope TA, Nickols NG, Czernin J, Calais J. Impact of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography on Prostate Cancer Salvage Radiotherapy Management: Results from a Prospective Multicenter Randomized Phase 3 Trial (PSMA-SRT NCT03582774). Eur Urol. 2024;86(1):52-60. doi:10.1016/j.eururo.2024.01.012
    AuntMinnie:PSMA-PET helps plan treatment in men with relapsed prostate cancer
  31. Farolfi A, Armstrong WR, Djaileb L, Gafita A, Hotta M, Allen-Auerbach M, Unterrainer LM, Fendler WP, Rettig M, Eiber M, Hofman MS, Hadaschik B, Herrmann K, Czernin J, Calais J, Benz MR. Differences and Common Ground in 177Lu-PSMA Radioligand Therapy Practice Patterns: International Survey of 95 Theranostic Centers. J Nucl Med. 2024;65(3):438-445. Published 2024 Mar 1. doi:10.2967/jnumed.123.266391
  32. L Emmett, N Papa, W Counter, J Calais, F Barbato, I Burger, M Eiber, MJ. Roberts, S Agrawal, A Franklin, A Xue, K Rasiah, N John, D Moon, M Frydenberg, J Yaxley, P Stricker, K W, G Coughlin, T Gianduzzo, B Kua, B Ho, A Nguyen, V Liu, J Lee, E Hsiao, T Sutherland, E Perry, WP Fendler, TA. Hope.Reproducibility and Accuracy of the PRIMARY Score on PSMA PET and of PI-RADS on Multiparametric MRI for Prostate Cancer Diagnosis Within a Real-World Database. J Nucl Med 2023 Nov 30: jnumed.123.266164. doi: 10.2967/jnumed.123.266164. PMID: 38050155
  33. Maliha PG, Hotta M, Czernin J, Calais J. Characterizing Normal Variant [68Ga]Ga-FAPI-46 Uptake in the Epididymis. J Nucl Med. 2023 Nov 9:jnumed.123.266013. doi: 10.2967/jnumed.123.266013. PMID: 37945382
  34. Sonni I, Gafita A, Unterrainer LM, Alano RM, Lira S, Shen J, Drakaki A, Grogan T, Rettig MB, Czernin J, Calais J. Effects of novel androgen receptor signaling inhibitors on PSMA PET signal intensity in patients with castrate-resistant prostate cancer: a prospective exploratory serial imaging study. EJNMMI Res. 2023 Oct 30;13(1):95. doi: 10.1186/s13550-023-01048-4. PMID: 37902861
  35. Meyer C, Stuparu A, Lueckerath K, Calais J, Czernin J, Slavik R, Dahlbom M. Tandem Isotope Therapy with 225Ac- and 177Lu-PSMA-617 in a Murine Model of Prostate Cancer. J Nucl Med. 2023 Nov;64(11):1772-1778. doi: 10.2967/jnumed.123.265433. PMID: 37797974
  36. Murthy V, Appiah-Kubi E, Nguyen K, Thin P, Hotta M, Shen J, Drakaki A, Rettig M, Gafita A, Calais J (Co-last author), Sonni I,. Associations of quantitative whole-body PSMA-PET metrics with PSA progression status under long-term androgen deprivation therapy in prostate cancer patients: a retrospective single-center study. Eur J Hybrid Imaging. 2023 Oct 2;7(1):18. doi: 10.1186/s41824-023-00178-1. PMID: 37779132.
  37. Koerber SA, Röhrich M, Walkenbach L, Liermann J, Choyke PL, Fink C, Schroeter C, Spektor AM, Herfarth K, Walle T, Calais J, Kauczor HU, Jaeger D, Debus J, Haberkorn U, Giesel FL
    Impact of 68Ga-FAPI PET/CT on Staging and Oncologic Management in a Cohort of 226 Patients with Various Cancers. J Nucl Med. 2023 Sep 7:jnumed.123.266046. PMID: 37678928
    AuntMinnie: FAPI-PET/CT may improve treatment of cancer patients
  38. Murthy V, Gafita A, Thin P, Nguyen K, Grogan T, Shen J, Drakaki A, Rettig M, Czernin J, Calais J. Prognostic Value of End-of-Treatment PSMA PET/CT in Patients Treated with 177Lu-PSMA Radioligand Therapy: A Retrospective, Single-Center Analysis. J Nucl Med. 2023 Sep 7:jnumed.122.265155. PMID: 37678927
  39. Hope TA, Benz M, Jiang F, Thompson D, Barbato F, Juarez R, Hernandez Pampaloni M, Allen-Auerbach M, Gupta P, Fendler WP, Calais J. Do Bone Scans Overstage Disease Compared with PSMA PET at Initial Staging? An International Multicenter Retrospective Study with Masked Independent Readers. J Nucl Med. 2023 Aug 17:jnumed.123.265916. PMID: 37591547
    UCSF: For Some Prostate Cancer Patients, PSMA PET May Be Better for Initial Staging of Disease
  40. Gafita A, Djaileb L, Rauscher I, Fendler WP, Hadaschik B, Rowe SP, Herrmann K, Calais J, Rettig M, Eiber M, Weber M, Benz MR, Farolfi A. Response Evaluation Criteria in PSMA PET/CT (RECIP 1.0) in Metastatic Castration-resistant Prostate Cancer. Radiology. 2023 Jul;308(1):e222148. doi: 10.1148/radiol.222148. PMID: 37432081
    Pluvicto patient response criteria validated
  41. Crane JN, Graham DS, Mona CE, Nelson SD, Samiei A, Dawson DW, Dry SM, Masri MG, Crompton JG, Benz MR, Czernin J, Eilber FC, Graeber TG, Calais J, Federman NC. Fibroblast Activation Protein Expression in Sarcomas. Sarcoma. 2023 Jun 9;2023:2480493. PMID: 37333052.
  42. Holzgreve A, Unterrainer M, Calais J, Adams T, Oprea-Lager DE, Goffin K, Lopci E, Unterrainer LM, Kramer KKM, Schmidt-Hegemann NS, Casuscelli J, Stief CG, Ricke J, Bartenstein P, Kunz WG, Mehrens D. Is PSMA PET/CT cost-effective for the primary staging in prostate cancer? First results for European countries and the USA based on the proPSMA trial. Eur J Nucl Med Mol Imaging. 2023 Jul 10. doi: 10.1007/s00259-023-06332-y. PMID: 37428216
  43. Djaïleb L, Armstrong WR, Thompson D, Gafita A, Farolfi A, Rajagopal A, Grogan TR, Nguyen K, Benz MR, Hotta M, Barbato F, Ceci F, Schwarzenböck SM, Unterrainer M, Zacho HD, Juarez R, Cooperberg M, Carroll P, Washington S, Reiter RE, Eiber M, Herrmann K, Fendler WP, Czernin J, Hope TA, Calais J. Presurgical 68Ga-PSMA-11 Positron Emission Tomography for Biochemical Recurrence Risk Assessment: A Follow-up Analysis of a Multicenter Prospective Phase 3 Imaging Trial. Eur Urol. 2023 Jul 21:S0302-2838(23)02955-X. PMID: 37482512
    Health Day: PSMA-PET Improves Prediction of Biochemical Recurrence in Prostate Cancer
    UCLA Health Newsroom: PSMA PET imaging improves accuracy of predicting prostate cancer recurrence
    Ecancer: PSMA PET imaging improves accuracy of predicting prostate cancer recurrence
    Urology Times: PSMA-PET shows value as a prognostic biomarker for recurrence in prostate cancer
  44. Fizazi K, Herrmann K, Krause BJ, Rahbar K, Chi KN, Morris MJ, Sartor O, Tagawa ST, Kendi AT, Vogelzang N, Calais J, Nagarajah J, Wei XX, Koshkin VS, Beauregard JM, Chang B, Ghouse R, DeSilvio M, Messmann RA, de Bono J. Health-related quality of life and pain outcomes with [177Lu]Lu-PSMA-617 plus standard of care versus standard of care in patients with metastatic castration-resistant prostate cancer (VISION): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2023 Jun;24(6):597-610. doi: 10.1016/S1470-2045(23)00158-4. PMID: 37269841
  45. Kuo PH, Yoo DC, Avery R, Seltzer M, Calais J, Nagarajah J, Weber WA, Fendler WP, Hofman MS, Krause BJ, Brackman M, Kpamegan E, Ghebremariam S, Benson T, Catafau AM, Kendi AT. A VISION Substudy of Reader Agreement on 68Ga-PSMA-11 PET/CT Scan Interpretation to Determine Patient Eligibility for 177Lu-PSMA-617 Radioligand Therapy. J Nucl Med. 2023 Aug;64(8):1259-1265. PMID: 37230533
  46. Hotta M, Gafita A, Murthy V, Benz MR, Sonni I, Burger IA, Eiber M, Emmett L, Farolfi A, Fendler WP, Weber MM, Hofman MS, Hope TA, Kratochwil C, Czernin J, Calais J. PSMA PET Tumor-to-Salivary Gland Ratio to Predict Response to [177Lu]PSMA Radioligand Therapy: An International Multicenter Retrospective Study. J Nucl Med. 2023 Mar 30:jnumed.122.265242. doi: 10.2967/jnumed.122.265242. PMID: 36997329 + Featured article of the month +
    Mirage News: New PSG Score Improves Patient Selection for PSMA Radiopharmaceutical Therapy
    Newly Developed PSG Score Improves Patient Selection for PSMA Radiopharmaceutical Therapy
    VJOncology: ASCO 2023 | PSMA PET ratio predicts response to [177Lu]PSMA radioligand therapy: a multicenter study
  47. Smith CP, Proudfoot JA, Boutros PC, Reiter RE, Valle L, Rettig MB, Nickols NG, Feng FY, Nguyen PL, Nagar H, Spratt DE, Attard G, Weiner A, Weidhaas JB, Calais J, Ma TM, Davicioni E, Xiang M, Kishan AU. Transcriptomic Heterogeneity in High-risk Prostate Cancer and Implications for Extraprostatic Disease at Presentation on Prostate-specific Membrane Antigen Positron Emission Tomography. Eur Urol Oncol. 2023 Mar 2:S2588-9311(23)00041-X. doi: 10.1016/j.euo.2023.02.009. PMID: 36870853
  48. Ma T, Czernin J, Felix C, Alano R, Wilhalme H, Valle L, Steinberg M, Dahlbom M, Reiter R, Rettig M, Cao M, Calais J, Kishan AU. LUNAR: a randomized Phase 2 study of 177 Lutetium-PSMA Neoadjuvant to Ablative Radiotherapy for Oligorecurrent Prostate Cancer (clinical trial protocol). BJU Int. 2023 Feb 16. doi: 10.1111/bju.15988. PMID: 36797449
  49. Smith CP, Xiang M, Armstrong WR, Nickols NG, Steinberg ML, Reiter RE, Rettig M, Weiner AB, Shen J, Valle L, Czernin J, Calais J, Kishan AU. Patterns of Failure in Men With Radiorecurrent Prostate Cancer: A Post Hoc Analysis of 3 Prospective Gallium 68 Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography Imaging Trials. Int J Radiat Oncol Biol Phys. 2023 Mar 1:S0360-3016(23)00181-5. PMID: 36863416
  50. Sonni I, Dal Pra A, O’Connell DP, Ells Z, Benz M, Nguyen K, Yoon SM, Deng J, Smith C, Grogan T, Nickols NG, Cao M, Kishan AU, Calais J. PSMA PET/CT-based Atlas for Prostatic Bed Recurrence after Radical Prostatectomy: Clinical Implications for Salvage Radiation Therapy Contouring Guidelines. J Nucl Med. 2023 Feb 9:jnumed.122.265025. doi: 10.2967/jnumed.122.265025. PMID: 36759200
    PSMA PET Improves Decision Making for Prostate Cancer Treatment
  51. Gudenkauf LM, Chavez M, Maconi ML, Geiss C, Seyedroudbari A, Thin P, Hoogland AI, Nguyen K, Murthy V, Armstrong WR, Komrokji K, Oswald LB, Jim HSL, El-Haddad G, Fendler WP, Herrmann K, Cella D, Czernin J, Hofman MS, Dicker AP, Calais J, Tagawa ST, Gonzalez BD. Developing a novel patient reported outcomes measure for prostate cancer patients receiving radionuclide therapy. J Nucl Med. 2023;64(6):869-872. doi:10.2967/jnumed.122.264946
    Moffit: Moffitt Researchers Develop Tool to Measure Patient Health and Well-Being after Radionuclide Therapy
  52. Meyer C, Prasad V, Stuparu A, Kletting P, Glatting G, Miksch J, Solbach C, Lueckerath K, Nyiranshuti L, Zhu S, Czernin J, Beer AJ, Slavik R, Calais J, Dahlbom M. Comparison of PSMA-TO-1 and PSMA-617 labeled with gallium-68, lutetium-177 and actinium-225. EJNMMI Res. 2022 Oct 1;12(1):65. doi: 10.1186/s13550-022-00935-6. PMID: 36182983
  53. Gafita A, Rauscher I, Fendler WP, Murthy V, Hui W, Armstrong WR, Herrmann K, Weber WA, Calais J, Eiber M, Weber M, Benz MR. Measuring response in metastatic castration-resistant prostate cancer using PSMA PET/CT: comparison of RECIST 1.1, aPCWG3, aPERCIST, PPP, and RECIP 1.0 criteria. Eur J Nucl Med Mol Imaging. 2022 Oct;49(12):4271-4281. doi: 10.1007/s00259-022-05882-x. PMID: 35767071
  54. Gafita A, Rauscher I, Weber M, Hadaschik B, Wang H, Armstrong WR, Tauber R, Grogan TR, Czernin J, Rettig MB, Herrmann K, Calais J, Weber WA, Benz M, Fendler WP, Eiber M. Novel framework for treatment response evaluation using PSMA-PET/CT in patients with metastatic castration-resistant prostate cancer (RECIP 1.0): an international multicenter study. J Nucl Med. 2022 Nov;63(11):1651-1658. PMID: 35422442 + SNMMI Alavi–Mandell Award 2023 +
  55. Morath V, Heider M, Mittelhäuser M, Rolbieski H, Stroh J, Calais J, Eiber M, Bassermann F, Weber WA. Initial evaluation of [18F]-FACBC for PET imaging of multiple myeloma. EJNMMI Res. 2022 Jan 31;12(1):4. doi: 10.1186/s13550-022-00876-0. PMID: 35099620
  56. Hotta M, Gafita A, Czernin J, Calais J.Outcome of patients with PSMA-PET/CT screen failure by VISION criteria and treated with 177Lu-PSMA therapy: a multicenter retrospective analysis. J Nucl Med. 2022 Oct;63(10):1484-1488. PMID: 35273096
    Cancer Network: Low/No PSMA Expressing mCRPC Tumors Respond Poorly to 177Lu-PSMA-617 Therapy
  57. Xiang M, Ma TM, Savjani R, Pollom EL, Karnes RJ, Grogan T, Wong JK, Motterle G, Tosoian JJ, Trock BJ, Klein EA, Stish BJ, Dess RT, Spratt DE, Pilar A, Reddy C, Levin-Epstein R, Wedde TB, Lilleby WA, Fiano R, Merrick GS, Stock RG, Demanes DJ, Moran BJ, Huland H, Tran PT, Martin S, Martinez-Monge R, Krauss DJ, Abu-Isa EI, Alam R, Schwen Z, Pisansky TM, Choo CR, Song DY, Greco S, Deville C, McNutt T, DeWeese TL, Ross AE, Ciezki JP, Boutros PC, Nickols NG, Bhat P, Shabsovich D, Juarez JE, Chong N, Kupelian PA, Rettig MB, Zaorsky NG, Berlin A, Tward JD, Davis BJ, Reiter RE, Steinberg ML, Elashoff D, Horwitz EM, Tendulkar RD, Tilki D, Czernin J, Gafita A, Romero T, Calais J, Kishan AU. Performance of a Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography-Derived Risk-Stratification Tool for High-risk and Very High-risk Prostate Cancer. JAMA Netw Open. 2021 Dec 1;4(12):e2138550. PMID: 34902034
    Health Imaging: PSMA PET/CT and Prostate Cancer Outcomes
    EurekAlert!: UCLA-led study provides first indirect evidence that PSMA PET/CT surpasses conventional imaging in detecting occult prostate cancer spread and predicting long-term course and outcomes
    Medscape: PSMA PET/CT Validated as Imaging Modality in Prostate Cancer
  58. Martin Ma T, Roy S, Wu X, Mantz C, Fuller D, Miszczyk L, Napieralska A, Namysł-Kaletka A, Bagshaw HP, Buyyounouski MK, Glicksman R, Andrew Loblaw D, Katz A, Upadhyaya SK, Nickols N, Steinberg ML, Philipson R, Aghdam N, Suy S, Pepin A, Collins SP, Boutros P, Rettig MB, Calais J, Wang M, Zaorsky N, Kishan AU.Refining the Definition of Biochemical Failure in the Era of Stereotactic Body Radiation Therapy for Prostate Cancer: the Phoenix Definition and Beyond. Radiother Oncol. 2021 Nov 10:S0167-8140(21)08797-1. doi: 10.1016/j.radonc.2021.11.005. PMID: 34774650
  59. Mona CE, Benz MR, Hikmat F, Grogan TR, Lückerath K, Razmaria A, Riahi R, Slavik R, Girgis MD, Carlucci G, Kelly KA, French SW, Czernin J, Dawson DW, Calais J. Correlation of 68Ga-FAPi-46 PET biodistribution with FAP expression by immunohistochemistry in patients with solid cancers: a prospective translational exploratory study. J Nucl Med. 2021 Nov 5:jnumed.121.262426. doi: 10.2967/jnumed.121.262426. PMID: 34740953
    AuntMinnie: PET imaging lays foundation for new cancer therapies
  60. Crompton J, Armstrong WR, Eckardt MA, Seyedroudbari A, Tap WD, Dry SM, Abt ER, Calais J, Herrmann K, Czernin J, Eilber FC, Benz MR. 18F-FLT PET/CT as a prognostic imaging biomarker of disease specific survival in patients with primary soft tissue sarcoma. J Nucl Med. 2022;63(5):708-712. doi:10.2967/jnumed.121.262502
  61. Sonni I, Felker ER, Lenis AT, Sisk AE, Bahri S, Allen-Auerbach MS, Armstrong WR, Suvannarerg V, Tubtawee T, Grogan T, Elashoff D, Eiber M, Raman SS, Czernin J, Reiter R, Calais J. Head-to-head comparison of 68Ga-PSMA-11 PET/CT and mpMRI with histopathology gold-standard in the detection, intra-prostatic localization and local extension of primary prostate cancer: results from a prospective single-center imaging trial. J Nucl Med. 2022;63(6):847-854. doi:10.2967/jnumed.121.262398
    + Featured article of the month +
    Urology Times: PSMA and MRI for Early Prostate Cancer Detection
  62. Ferdinandus J, Fendler WP, Farolfi A, Washington S, Mohammad O, Pampaloni MH, Scott PJ, Rodnick M, Viglianti BL, Eiber M, Herrmann K, Czernin J, Armstrong WR, Calais J, Hope TA, Piert MA. PSMA PET validates higher rates of metastatic disease for European Association of Urology Biochemical Recurrence Risk Groups: an international multicenter study. J Nucl Med. 2022;63(1):76-80. doi:10.2967/jnumed.121.262821
    + SNMMI Alavi–Mandell Award 2023 +
    Health Imaging: EUAs and Prostate Cancer Recurrence Risk
  63. Abghari-Gerst M, Armstrong WR, Nguyen K, Calais J, Czernin J, Lin D, Jariwala N, Rodnick M, Hope TA, Hearn J, Montgomery JS, Alva A, Reichert ZR, Spratt DE, Johnson TD, Scott PJH, Piert M. A comprehensive assessment of 68Ga-PSMA-11 PET in biochemically recurrent prostate cancer: Results from a prospective multi-center study in 2005 patients. J Nucl Med. 2022;63(4):567-572. doi:10.2967/jnumed.121.262412
    Health Imaging: PSMA PET in UCLA Prostate Cancer Research
    DocWire News: 68Ga-PSMA-11 PET Specificity for Pelvic Nodal Metastases
  64. Hope TA, Eiber M, Armstrong WR, Juarez R, Murthy V, Lawhn-Heath C, Behr SC, Zhang L, Barbato F, Ceci F, Farolfi A, Schwarzenböck SM, Unterrainer M, Zacho HD, Nguyen HG, Cooperberg MR, Carroll PR, Reiter RE, Holden S, Herrmann K, Zhu S, Fendler WP, Czernin J, Calais J. Diagnostic Accuracy of 68Ga-PSMA-11 PET for Pelvic Nodal Metastasis Detection Prior to Radical Prostatectomy and Pelvic Lymph Node Dissection: A Multicenter Prospective Phase 3 Imaging Trial. JAMA Oncol. 2021;7(11):1635-1642. doi:10.1001/jamaoncol.2021.3771
    Health Imaging: ‘Practice changing’: New research underscores clinical benefits of PSMA-PET for prostate cancer
    GU Oncology Now: 68Ga-PSMA-11 PET Has Specificity of 0.95 for Pelvic Nodal Metastases

Research Areas

Main Focus of Research

I. Prostate Specific Membrane Antigen Theranostics to improve prostate cancer patient outcome.

The Theranostics Clinical Research Program is conducting clinical trials to determine the impact of PSMA PET imaging and PSMA radionuclide therapy on care and outcome of patients with prostate cancer.

 

Figure 1 : Example of a patient with metastatic castrate resistant prostate cancer responding to Lu177-PSMA radionuclide therapy.

 

Figure 2 : This figure shows in yellow multiple prostate cancer lesions detected by PSMA PET/CT that are outside of the standard radiation fields (green and orange fields) that would therefore fail.

II. Fibroblast activated protein as new target for nuclear theranostics.

Dr Jeremie Calais has designed and initiated at UCLA exploratory clinical studies of FAPI PET targeting the tumor stroma (fibroblast activation protein) in multiple cancers. FAP is a new promising target for nuclear Theranostics.

Figure 4: FAP-target for nuclear Theranostics

Academic Research

FDA New Drug Application NDA #212642 for PSMA-11 Gallium-68

Role: Co-Investigator and clinical study report author
– UCLA and UCSF joint application (Principal Investigators: Johannes Czernin and Thomas A Hope)
– Indication: PSMA-11 Ga 68 Injection for PET Imaging of Detection and Localization of Prostate Cancer

FDA New Drug Application NDA #130342 for Fluor-18-Choline

Role: Co-Investigator and Blinded Independent Central Reader (BICR)
– UCSF and UCLA joint application (Principal Investigator: Thomas A Hope)
– Indication: Fluor-18 Choline for PET Imaging of Detection and Localization of parathyroid hyperactivity

Prospective Clinical Trial:

  • 68Ga-PSMA-11 PET/CT for the Diagnosis of Bone Metastases in Patients With Prostate Cancer and Biochemical Progression During Androgen Deprivation Therapy
    ClinicalTrials.gov Identifier: NCT04928820
    Start date: June, 2021
  • 99mTc-PSMA-I&S Biodistribution in Patients With Prostate Cancer
    ClinicalTrials.gov Identifier: NCT04857502
    Start date: June, 2021
  • Randomized Trial of PSMA PET Scan Before Definitive Radiation Therapy for Prostate Cancer (PSMA DRT)
    ClinicalTrials.gov Identifier: NCT04457245
    Start Date: Sept 2020
  • 68Ga-FAPi-46 PET/CT Scan in Imaging Patients With Sarcoma
    ClinicalTrials.gov Identifier: NCT04457258
    Start Date: Sept 2020
  • Prospective Exploratory Study of FAPi PET/CT With Histopathology Validation in Patients With Various Cancers (FAPI PET RDRC)
    ClinicalTrials.gov Identifier: NCT04459273
    Start Date: Sept 2020
  • Prospective Exploratory Study of FAPi PET/CT in Prostate Cancer With Histopathology Validation (FAPI PET Prost)
    ClinicalTrials.gov Identifier: NCT04457232
    Start Date: Sept 2020
  • PET biodistribution study of 68Ga-PSMA-11 and 68Ga-FAPI-46 in patients with non-prostate cancers: an exploratory study with histopathology validation
    ClinicalTrials.gov Identifier: NCT04147494
    Start Date: Oct 2019
  • Expanded Access Protocol of 68Ga-PSMA-11 for Prostate Cancer PET Imaging
    Protocol No.: NCT04348682
    Start Date: Mar 2020
  • Effect of Androgen Receptor Signaling Inhibitors on 68Ga-PSMA-11 PET/CT Imaging in Patients With Metastatic Castration-Resistant Prostate Cancer
    ClinicalTrials.gov Identifier: NCT04279561
    Start Date: Mar 2020
  • Evaluation by 68Ga-PSMA-11 PET imaging of Monosodium Glutamate as a potential agent for Salivary Gland Protection under PSMA-targeted alpha-therapy: a randomized pilot imaging research study
    Protocol Number: NCT04282824
    Start Date: Jan 2020
  • Randomized phase 3 Trial of 68Ga-PSMA-11 PET/CT Molecular Imaging for Prostate Cancer Salvage Radiotherapy Planning [PSMA-SRT]
    ClinicalTrials.gov Identifier: NCT03582774
    Start date: July 12, 2018
  • 99mTc-SestaMIBI SPECT/CT Imaging for the Characterization of Renal Masses: Impact on Clinical Decision Making
    ClinicalTrials.gov Identifier: NCT03996850
    Start Date: Dec 7, 2018
  • Impact of 68Ga-PSMA-11 PET/CT on initial and subsequent treatment strategies of patients with prostate cancer.
    ClinicalTrials.gov Identifier: NCT04050215
    Start Date: Apr 7, 2018
  • PSMA-directed endoRadiothErapy of Castration-reSISTant Prostate Cancer (RESIST-PC). A Phase II Clinical Trial
    ClinicalTrials.gov Identifier: NCT03042312
    Start Date: July 12, 2017
  • Prospective Single Center Trial to Compare 68Ga-PSMA-11 and Axumin PET/CT (18F-Fluciclovine) for Restaging Prostate Cancer Patients With Biochemical Recurrence After Radical Prostatectomy
    ClinicalTrials.gov Identifier: NCT03515577
    Start date: March 2, 2018
  • 68Ga-PSMA PET/CT for Detection of Recurrent Prostate Cancer After Initial Therapy
    ClinicalTrials.gov Identifier: NCT02940262
    Start date: September 5, 2016
  • 68Ga-PSMA-11 PET/CT for Staging of Intermediate and High Risk Prostate Cancer Prior to Radical Prostatectomy
    ClinicalTrials.gov Identifier: NCT03368547
    Start Date: December 12, 2016

Biopharma Industry Sponsored Research

  • SPLASH: Study Evaluating mCRPC Treatment Using PSMA [Lu-177]-PNT2002 Therapy After Second-line Hormonal Treatment
    ClinicalTrials.gov Identifier: NCT04647526
    Sponsor: POINT biopharma.
    Start Date: Oct , 2021
  • 177Lu-PSMA-617 Managed Access Program for mCRPC Patients
    ClinicalTrials.gov Identifier: NCT04825652
    Sponsor: Novartis.
    Start Date: July 2021
  • ARROW: Study of I-131-1095 Radiotherapy in Combination With Enzalutamide in Patients With Metastatic Castration-resistant Prostate Cancer Who Are Chemotherapy Naive and Have Progressed on Abiraterone
    ClinicalTrials.gov Identifier: NCT03939689
    Sponsor: Progenics Pharmaceuticals, Inc.
    Start Date: Dec , 2020
  • ZIRCON: 89Zr-TLX250 for PET/CT Imaging of ccRCC- ZIRCON Study (89ZR-TLX250)
    ClinicalTrials.gov Identifier: NCT03849118
    Sponsor: Telix International Pty Ltd.
    Start Date: Dec, 2020
  • VISION: An International, Prospective, Open Label, Multicenter, Randomized Phase 3 Study of 177Lu-PSMA-617 in the Treatment of Patients With Progressive PSMA-positive Metastatic Castration-resistant Prostate Cancer (mCRPC)
    ClinicalTrials.gov Identifier: NCT03511664
    Sponsor: Endocyte Inc.
    Start Date: Dec 7, 2018
  • AMG160: A Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Prostate Specific Membrane Antigen Half-life Extended Bispecific T-cell Engager AMG 160 in Subjects With Metastatic Castration-resistant Prostate Cancer
    ClinicalTrials.gov Identifier: NCT03792841
    Sponsor: Amgen Inc.
    Start Date: Dec 7, 2018
  • A Multicentre, Randomised, Dose-confirmation, Factorial Phase II Study to Evaluate the Optimal Dose of 68Ga-OPS202 as a PET Imaging Agent in Subjects With Gastroenteropancreatic Neuroendocrine Tumour (GEP-NET)
    ClinicalTrials.gov Identifier: NCT03220217
    Sponsor: Ipsen Inc.
    Start Date: Sep 20, 2017

Section

Selected Videos:

Podcasts